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Mesenchymal stem/stromal cells (MSCs) represent a promising adult progenitor cell source for tissue repair and regeneration.
Their mysterious identity in situ has gradually been unveiled by the accumulating evidence indicating an association between adult
multipotent stem/progenitor cells and vascular/perivascular niches. Using immunohistochemistry and fluorescence-activated cell
sorting, we and other groups have prospectively identified and purified subpopulations of multipotent precursor cells associated
with the blood vessels within multiple human organs. The three precursor subsets, myogenic endothelial cells (MECs), pericytes
(PCs), and adventitial cells (ACs), are located, respectively, in the three structural tiers of typical blood vessels: intima, media,
and adventitia. MECs, PCs, and ACs have been extensively characterized in prior studies and are currently under investigation
for their therapeutic potentials in preclinical animal models. In this review, we will briefly discuss the identification, isolation,
and characterization of these human blood-vessel-derived stem cells (hBVSCs) and summarize the current status of regenerative
applications of hBVSC subsets.
1. Introduction
Adult multipotent stem/progenitor cells are promising cell
sources for tissue repair and regeneration because of their
self-renewal, differentiation capacity, and secretion of trophic
factors [1]. Though developmentally not as versatile as
embryonic stem cells (ESCs) or induced pluripotent stem
cells (iPSCs), adult stem/progenitor cells represent a more
clinically relevant cell source for regenerative medicine
due to less ethical and/or safety issues [2]. In particular,
mesenchymal stem/stromal cells (MSCs) andMSC-like mul-
tilineage precursor cells, including adipose-derived stem cells
(ADSCs), mesoangioblasts, andmultipotent adult progenitor
cells (MAPCs), have attracted significant clinical attentions,
largely owing to their accessibility aswell as the robust trophic
and immunosuppressive functions.
It has been more than a decade since the first discovery
of MSCs and similar precursor cells in human bone marrow
(BM), adipose, placenta, and many other tissues [3–5].
TypicalMSCs are plastic-adherent and expressing cell surface
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markers such as CD29 (integrin-𝛽1), CD44 (hyaluronic
acid receptor), CD73 (ecto-5󸀠-nucleotidase), CD90 (Thy-
1), CD105 (endoglin) but negative for CD14 (myeloid cell-
specific leucine-rich glycoprotein), CD31 (PECAM-1), CD34
(hematopoietic/stem/endothelial cell marker), and CD45
(pan-leukocyte marker), in addition to the capacity of differ-
entiating into common mesodermal cell lineages including
osteoblasts, chondroblasts, and adipocytes. However, BM
titers of human MSCs decline significantly with age [6].
Recently, clonally derivedMSCs injected intra-arterially have
been shown to selectively engraft at perivascular locations
in the BM sinusoids/microvessels following a localized radi-
ation injury in the mouse hindlimb [7]. Engrafted MSCs
can not only proliferate locally in the long-term but also be
serially transplanted into the secondary host while maintain-
ing similar homing and engraftment efficiency. These results
imply that BMcan be therapeutically exploited as a renewable
source for exogenous MSC transplantation.
Despite the extensive investigation, the native identity
of MSCs has long been obscured by the retrospective iden-
tification method in culture. Recently, there is increasing
evidence indicating the relationship between tissue-specific
stem/progenitor cells and vascular/perivascular niches [8, 9]
as well as the presence of multipotent stem cells of vascular
origin [10–12]. Sacchetti et al. demonstrated that CD146+
subendothelial stromal cells residing on the BM sinusoidal
wall not only self-renew and display vascular mural cell
features but also form bone and establish the hematopoietic
microenvironment [13]. Consequently, a hypothesis that
blood vessels throughout the human body serve as a reservoir
of multipotent precursor cells has been formulated [14, 15].
Using immunohistochemical assays and fluorescence-
activated cell sorting (FACS), we and other researchers
have prospectively identified and purified three populations
of multipotent precursor cells from human blood vessels:
myogenic endothelial cells (MECs), pericytes (PCs), and
adventitial cells (ACs). Collectively named human blood-
vessel-derived stem cells (hBVSCs), these subpopulations of
hBVSCs can be isolated from blood vessels within human
skeletal muscle, with each expressing a unique profile of
cell surface antigens. PCs and ACs have also been iso-
lated from several other human tissues such as fat and
lung [16–19]. MECs, PCs, and ACs all possess common
mesodermal multipotency and display typical MSC markers,
suggesting their contributions to the heterogeneous MSC
entity.
2. Native Distribution of Human
Blood-Vessel-Derived Stem Cells
Human blood vessels typically consist of three definitive
structural tiers: tunica intima, tunica media, and tunica
adventitia [20]. Tunica intima is the innermost layer of a
blood vessel and primarily composed of endothelial cells
(ECs), supported by an abluminal layer of elastic fibers.
Tunica media contains multiple layers of smoothmuscle cells
(SMCs) while tunica adventitia, the outermost layer, consists
of extracellular matrix (ECM), fibroblast-like stromal cells,
and vasa vasorum. At themicrovessel (arterioles and venules)
and capillary level, the construction of vessels is reduced to
only endothelial cells and surrounding vascular stromal cells
(VSCs), that is, pericytes. The EC-to-PC ratio ranges from
100 : 1 to 1 : 1 while PC coverage of abluminal EC surface varies
from 10% to 50%, depending on the tissue origin [21]. Increas-
ing evidence indicated the existence of pericyte-like cells
in normal intima, suggesting a heterogeneous PC network
within blood vessels of all sizes [22, 23]. Moreover, compara-
tive characterization studies have demonstrated differences in
expression of cell lineage markers, developmental potentials,
and angiogenic capacity among human VSCs derived from
the walls of blood vessels of different sizes (artery, vein,
and microvessel) [24]. These results imply innate differences
between VSCs residing in different vascular structural tiers
and tissue-dependent divergence of VSCs.
Developmentally myogenic cells (MCs) and ECs of the
vertebrate limbmay derive froma common somitic precursor
[25]. Notch signaling has recently been shown to play an
important role in the selection of endothelial versusmyogenic
cell fate in multipotent somitic Pax3+ cells before their
migration to the limbs during embryonic development [26].
Previous studies showed that cells coexpressing MC and EC
markers reside within the interstitial space of skeletal muscle
and possibly contribute to postnatal muscular development
[27]. Consequently we hypothesized that an intermediate
cell type coexpressing MC and EC markers exists within
the interstitium of postnatal skeletal muscle, presumably
associated with blood vessels and potentially multipotent.
Indeed, immunohistochemistry revealed that a rare subset of
myogenic precursor cells coexpresses MC and EC markers
at the microvascular level [28]. These myogenic endothelial
cells (MECs) not only express MC markers including Pax7
and CD56 but also display EC markers including CD34,
CD144 (VE-cadherin), von Willebrand factor (vWF), and
Ulex europaeus agglutinin-1 (UEA-1) [28].
Pericytes (PCs) are commonly regarded as a structural
component of small blood vessels that regulate vascular con-
tractility, stability, and integrity [29–31]. PCs also modulate
EC proliferation/vascular remodeling and are involved in
specialized vascular functions including blood-brain barrier
and renal tubulovesicular coordination as well as several
pathological conditions [21, 23, 32–35]. However, this par-
ticular cell population has not been well defined in most
of the human organs due to a lack of representative cell
marker(s). We previously described microvascular PCs in
multiple human tissues based on robust expression of CD146
(Mel-CAM), NG2 (chondroitin sulphate), platelet-derived
growth factor receptor-beta (PDGFR𝛽), and the absence of
myogenic (CD56), hematopoietic (CD45), and endothelial
cell surface markers (CD31, CD34, CD144, and vWF) [16].
Alkaline phosphatase (ALP) is another marker used to typify
PCs in human skeletal muscle [36, 37]. Alpha-smoothmuscle
actin (𝛼-SMA), on the other hand, can be detected in PCs
encircling arterioles and venules but not in those surrounding
most capillaries [16]. PCs in situ also express classic MSC
markers: CD44, CD73, CD90, and CD105 [16].
Adventitial cells (ACs) have been perceived as fibroblast-
like cells producing adventitial ECM, a loose structural
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element enclosing media of arteries and veins. Recent
studies indicated that CD34 identifies 2 concentric rings
of cells residing in intima and adventitia, respectively [38].
Specifically, the CD34+/CD31−/CD45−/CD146− cell subset
localized within adventitia, distinct from typical CD34+
endothelial progenitor cells (EPCs), was shown to possess
stem/progenitor cell properties and actively participate in
vascular pathophysiology [39, 40]. In a vascular injurymodel,
ACs initiated a remodeling process by proliferating and
migrating into media and intima and further differenti-
ated into smooth muscle cells, suggesting the importance
of adventitia in vascular cell trafficking and blood-vessel
remodeling [41, 42]. Furthermore, ACs located in the “vas-
culogenic zone,” that is, the interface between tunica media
and adventitia, have been described as precursors endowed
with the capacity to differentiate into endothelial cells and
participate in the blood-vessel formation as well as the
pathogenesis of atherosclerosis [42–44]. Similar to PCs, there
is increasing data suggesting a wide distribution of CD34+
perivascular stromal cells, even at the microvascular level
[45].
3. Purification of Human
Blood-Vessel-Derived Stem Cells
Based on the cell surface marker expression identified by
immunohistochemistry, we discovered a unique combination
of surface antigens for each subset of hBVSCs that allows one
to purify these cells to homogeneity through FACS: MECs
(CD34+/56+/144+/45−), PCs (CD146+/34−/45−/56−), and
ACs (CD34+/31−/45−/56−/146−) [16, 18, 28]. The isolation
and purification of hBVSC subpopulations have been well
established [46]. The workflow of hBVSC purification from
fresh human skeletal muscle biopsy is illustrated in Figure 1.
To date, skeletalmuscle is the only human tissue that has been
shown to contain all three hBVSC subsets, with MECs not
yet identified in other adult human organs. To isolate PCs
and ACs from human adipose, fresh biopsy or lipoaspirate is
dissociatedmechanically and enzymatically to obtain stromal
vascular fraction (SVF), followed by similar cell labeling
and sorting processes [16, 18, 47]. PCs can also be purified
from human placenta, pancreas, skin, heart, and other organs
following a similar protocol [16, 48]. ACs, on the other hand,
can be isolated from other human tissues including lung and
BM or directly from blood vessels such as saphenous vein
[19].
MECs exist at a very low frequency (<0.5%) within the
vasculature of human skeletal muscle [28]. On the contrary,
PCs can be found in many human tissues at different
proportions, for example, 0.29 ± 0.09% in adult skeletal
muscle, 0.88 ± 0.18% in fetal skeletal muscle, 0.65 ± 0.10% in
adult pancreas, 1.68 ± 0.78% in placenta, and 1.21 ± 0.52%
in myocardium [16, 17, 48]. Adipose SVF contains higher
frequencies of PCs (14.6 ± 1.02%) due to the abundance of
microvasculature in human fat and enrichment of vessel-
associated cells during the isolation procedure [16]. On the
other hand, ACs represent 9.8 ± 1.7% of the intact adipose
SVF and up to 23.8% of SVF from human lipoaspirate
for the same reason [18, 47]. In contrast, we found only
2.70 ± 1.01% ACs in human skeletal muscle (unpublished
data). Further investigation is needed to determine whether
the native frequency of each hBVSC subset changes with
multiple physiological parameters, such as age and gender,
and/or pathological conditions.
4. Characterization of Human
Blood-Vessel-Derived Stem Cells
After FACS purification, hBVSCs subpopulations can be
either examined/utilized freshly or further expanded in
culture [16–18, 47]. MECs, PCs, and ACs have been indepen-
dently shown to possess mesenchymal differentiation capac-
ities including chondrogenesis, osteogenesis, adipogenesis,
and skeletal myogenesis in vitro and express classic MSC
markers such as CD44, CD73, CD90, and CD105 natively or
in culture [16, 18, 28, 36, 49].
MECs not only proliferated at a significantly higher rate
than sorted CD56+MCs and CD34+/144+ ECs, even in low-
serum culture conditions, but also were more resistant to cell
death when cultivated under oxidative stress (400𝜇MH
2
O
2
)
[28]. PCs, freshly sorted or long-term cultured, frommultiple
tissues including adipose, placenta, and pancreas exhibited
a similar level of skeletal myogenesis in vitro as muscle-
derived PCs, suggesting a generalized myogenic potential
of PCs in the human body [16]. In addition, PCs displayed
strong chemotactic response toward papain/pepsin digested
ECM harvested from porcine urinary bladder and formed
capillary-like structures with/without ECs in two- and three-
dimensional Matrigel cultures/cocultures [16, 50]. Similar
to PCs, ACs derived from different tissue origins showed
the same phenotype and robust mesodermal developmental
potentials, suggesting that MSCs can be derived from an
alternative systemic source which is distinct from PCs [18].
In regular culture, ACs did not express any of the cultured
PC markers including NG2, 𝛼-SMA, CD146, and PDGFR𝛽
but shared the expression of vimentin with PCs [18]. The
cellular kinetics of hBVSC subsets was recently reviewed in
[51].
To further investigate whether hBVSC subsets meet the
criteria of bona fide stem cells, we obtained clones of MECs,
PCs, and ACs through either FACSAria autoclone system or
limiting dilutions [16, 18, 28, 49]. At the clonal level, all three
hBVSC subsets indeed exhibited typical MSCmarkers as well
as robust mesenchymal differentiation capacities in culture
[16, 18, 28, 49]. Consequently we theorized that hBVSC
subsets are genuine ancestors of MSCs. Interestingly, it has
been shown that ACs proliferate significantly faster than PCs
and partially express aforementioned PC markers following
treatment of angiopoietins-2 or angiotensin-II, suggesting
adaptation of PC phenotypes and/or differentiation into PC-
like cells upon stimulation [18].Therefore it is speculated that
ACs serve as the progenitor of pericytes [18, 52]. Nevertheless,
future studies with appropriate cell lineage tracking will
be required to convincingly establish the hierarchy and
developmental relationship among hBVSC subpopulations
and between various vascular/perivascular cell populations
[53].
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Figure 1: Schematic depiction of hBVSC purification from human skeletal muscle biopsy. Vascular/perivascular cells residing in the blood
vessels within the interstitial space of human muscle fibers include endothelial cells (ECs, green), myogenic endothelial cells (MECs, red),
pericytes (PCs, yellow), and adventitial cells (ACs, blue). All cells, including immature/mature myocytes and muscle stem cells (i.e., satellite
cells), aremechanically and enzymatically dissociated from freshmuscle biopsy. Dissociated cells are subsequently purified to homogeneity by
fluorescence-activated cell sorting (FACS). Newly sortedMECs, PCs, and ACs readily exhibit multilineage developmental potentials. Purified
PCs, ACs, and possibly MECs give rise to authentic MSCs in long-term culture. However, whether other stem/stromal cells participate in the
MSC entity remains to be tested.Moreover, whether native hBVSCs function as typicalMSCs in situ and/or actively repair/regenerate defective
tissues require further investigation.
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Figure 2: Potential translational applications of hBVSC subpopu-
lations. The current translational applications of typical MSCs are
summarized on the right.The current status of translational research
for each hBVSC subset is outlined, whether the specific application
has been tested or is presently under investigation.
5. Regenerative Applications of
Human Blood-Vessel-Derived Stem Cells
As we described above, each hBVSC subset has been shown
to display stem cell characteristics and exhibit mesodermal
multipotency upon appropriate induction. In addition, all
three hBVSC subpopulations have been demonstrated to
serve as robust paracrine units, even under stress con-
ditions [50, 52, 54]. However, the relative significance of
paracrine function, direct differentiation, and cellular inter-
action by individual hBVSC subtype may depend on spe-
cific pathological conditions and corresponding regenerative
actions. Figure 2 summarizes putative applications of all three
hBVSC subpopulations in regenerative medicine. A number
of representative applications will be discussed in detail
below.
5.1. Skeletal Muscle Regeneration
5.1.1. Myogenic Endothelial Cells. Because of their high
myogenic potential in vitro, MECs have been tested for
muscle regeneration in immunodeficient mouse models of
cardiotoxin-induced muscle injury and Duchenne muscular
dystrophy [28]. The superior myogenic capacity of MECs
over typical CD56+ MCs, CD34+/144+ ECs, and unpuri-
fied human primary skeletal muscle cells (hPSMCs) was
demonstrated by substantially more regenerating human
spectrin-positive myofibers after intramuscular injections
into cardiotoxin-injured mouse hindlimb muscles [28].
Moreover, to clarify whether newly regenerated human
myofibers originated only from the differentiation/fusion of
donor cells or in fact involved the participation of host cells,
in situ hybridization with mouse X chromosome-specific
probe was performed. None of the nuclei within the human
spectrin-positive myofibers were identified by the mouse-
specific probe, confirming their solely human origin [28]. In
addition, regeneration of myofibers coexpressing dystrophin
and human lamin A/C was observed in dystrophic mouse
muscles after injections of human MECs in mdx/SCID mice
[28]. Intriguingly, MECs can also be identified/isolated in
nonvertebrates such as leech and directly participate in
myogenesis in vitro and in vivo, similar to their verte-
brate counterparts [55]. Recently, the murine counterpart of
human MECs was shown to play a role in skeletal muscle
homeostasis, inhibiting intramuscular adipogenesis through
cell-autonomous and cell-cell interactive mechanisms with
active Bmpr1a signaling [56]. Together these data suggest that
MECs remain an evolutionarily conserved, distinctmyogenic
precursor population which actively participates in muscle
homeostasis and regeneration and possibly bridges MC and
EC during muscle development.
5.1.2. Pericytes. The application of PCs in muscle regener-
ation was examined in immunodeficient mouse models of
cardiotoxin-induced muscle injury and Duchenne muscular
dystrophy [16, 17, 36]. Freshly sorted or cultured PCs from
human muscle and adipose were injected directly into the
cardiotoxin-injured gastrocnemius muscles of SCID/NOD
mice [16]. PCs from either tissue source regenerated more
human spectrin-positive myofibers than purified MCs or
ECs, indicating the authentic myogenic capacity of PCs
[16]. Similarly, injections of placental PCs into dystrophic
gastrocnemius muscles in SCID/mdx mice not only yielded
more dystrophin-positive myofibers but also increased the
number of local vWF-positive microvasculatures [17]. The
human origin of regenerating myofibers was confirmed by in
situ hybridization with human-specific probe, coexpression
of human lamin A/C, or GFP-based cell tracking [16, 17].
Dellavalle et al. further demonstrated that, through ALP-
based cell lineage tracking, native PCs residing in the skeletal
muscle participate in the postnatal myofiber development,
especially under pathological conditions, and contribute to
the satellite cell compartment [37]. These results reflect
the robust myogenic potential of PCs in vivo that can be
generalized to PCs frommore clinically accessible nonmuscle
tissues like adipose and placenta.
Nevertheless, not all PCs within the skeletal muscle are
myogenic and contributing to muscle formation. Birbrair
et al. reported the presence of two subtypes of PCs within
the skeletal muscle: the adipogenic Nestin−/NG2+ (type-
1) and myogenic Nestin+/NG2+ (type-2) PCs [57]. Only
type-1 PCs expressed PDGFR𝛼, an adipogenic progenitor
marker, and contributed exclusively to fat deposition but not
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myofiber formation after muscle injury [57]. Future research
is needed to determine whether successful muscle regen-
eration depends on a dynamic balance between myogenic
type-2 and nonmyogenic type-1 PCs and/or other myogenic
and nonmyogenic stem/progenitor cells [58]. Additionally,
whether PDGFR𝛼+ adipogenic PCs contribute to patho-
logical fat accumulation in myopathies and muscle ageing
and their relationship with mesenchymal fibro-adipogenic
precursors requires further investigation [59]. These results
also imply that separation of subtypes of muscle PCs may be
necessary to increase the myogenic efficacy of PC treatment
in injured/diseased muscle.
5.2. Vascular Regeneration
5.2.1. Myogenic Endothelial Cells. MECs have been shown to
form capillary structures in Matrigel culture and implanted
Matrigel plugs, suggesting that MECs retain their vascular
traits and angiogenic properties in vitro and in vivo, even
after long-term culture [49]. Another vascular progenitor
cell (VPC) population coexpressing endothelial and myo-
genic cell markers (CD34+/133+/KDR+/desmin+) has been
derived from human fetal aorta [60]. Upon being trans-
planted into ischemicmuscles, thesemyogenicVPCsnot only
alleviated the symptomatic outcome but also incorporated
into regenerating myofibers and microvessels in a murine
model of hindlimb ischemia [60]. Altogether these studies
indicate reparative and regenerative capacities of MECs for
angiogenesis and revascularization.
5.2.2. Pericytes. To investigate their capacity for vascular
repair, PCs were seeded onto small-diameter, bilayered elas-
tomeric poly(ester-urethane)urea scaffolds and incubated
in bioreactors for 2 days before being implanted as aortic
interposition grafts in Lewis rats for 8 weeks [61]. PC-seeded
grafts showed a significantly higher patency rate (100%)
than unseeded controls (38%) and exhibited extensive tissue
remodeling including elastin/collagen deposition, multiple
layers of 𝛼-SMA- and calponin-positive cells, and a mono-
layer of vWF-positive cells in the lumen, indicating the
potential of PCs in vascular repair and tissue engineering [61].
Nonetheless, contrary to their typical angiogenic role in tissue
repair, PCs were recently demonstrated to inhibit microves-
sel formation and further induce microvessel dissociation
through CXCR3-induced involution of ECs in an in vitro
angiogenic model [62]. These results suggest multifaceted
regulatory functions of PCs in vascular repair/regeneration,
not only promoting angiogenesis/vasculogenesis but also
contributing to the pruning of excessive/immature microves-
sels during tissue repair.
5.2.3. Adventitial Cells. The regenerative applications of ACs
have primarily been focused on cardiovascular diseases thus
far [63]. As described above, ACs actively engage in not
only the physiological maintenance but also the pathological
remodeling of blood vessels [64]. Consequently, harnessing
the restorative power of ACs is key to the success of treating
vascular diseases such as atherosclerosis and restenosis of
vascular grafts [44, 65].
ACs (CD34+/31−) localized around adventitial vasa vaso-
rum of the human saphenous vein (i.e., adventitial pericytes)
have been shown to express typical MSC and certain PC
antigens and displayed clonogenic and multilineage dif-
ferentiation capacities, similar to ACs derived from other
tissues [19]. ACs promoted the formation and stabilization
of microvessel-like structures in vitro, likely through the
reciprocal AC-EC interactions and paracrine cross-talk that
can be inhibited by Tie-2 or PDGF-BB blockade [19]. Intra-
muscular injections of ACs in an immunodeficient mouse
model of hindlimb ischemia revealed a significant angiogenic
effect and facilitated near-full recovery of blood flow by as
early as 7 days after injection [19]. ACs remained detectable
after 14 days, interacting with host ECs through N-cadherin.
These results indicate the potential of ACs in therapeutic
angiogenesis/vasculogenesis, especially for the treatment of
ischemic diseases. Lately, ACs have been shown to exhibit
higher resistance to oxidative stress than ECs due to increased
expression of antioxidant enzymes including catalase and
superoxide dismutases (SODs) [66]. Silencing the extracel-
lular, soluble isoform of superoxide dismutase (SOD3) in
ACs resulted in the negation of their therapeutic benefit
on blood flow recovery and neovascularization in a mouse
model of peripheral ischemia, suggesting the involvement of
SOD3 released byACs in ischemic protection and/or vascular
healing [66].
5.3. Cardiac Regeneration
5.3.1. Myogenic Endothelial Cells. The therapeutic poten-
tial of MECs in ischemic heart disease was investigated
in an immunodeficient mouse model of acute myocardial
infarction (AMI) [54]. Myocardial infarction (MI) was first
induced by ligating the anterior descending branch of the
left coronary artery. Cultured MECs, MCs, and ECs were
intramyocardially injected into the ischemic myocardium
immediately after the induction of MI [54]. When compared
with injections of MCs and ECs, a significant improvement
in cardiac contractility was recorded by echocardiography
after MEC treatment [54]. Transplanted MECs attenuated
ventricular fibrosis, enhanced proliferation and survival of
host cardiomyocytes, and promoted local angiogenesis more
effectively than MCs and ECs [54]. Despite the robust
engraftment of MECs within the infarcted myocardium, only
a few differentiated/transdifferentiated into cardiomyocytes
[54]. Consequently the functional recovery of MEC-injected
hearts resulted primarily from the greater paracrine secretion
of trophic factors, especially vascular endothelial growth
factor (VEGF), by MECs under hypoxia.
5.3.2. Pericytes. The therapeutic potency of PCs in car-
diac regeneration has been investigated. Human muscle-
derived PCs were injected into the ischemic myocardium
immediately after the induction of MI in a SCID/NOD
mouse model [50]. Echocardiography revealed that PC treat-
ment attenuated left ventricular dilatation and significantly
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Figure 3: Resident microvascular pericytes in humanmyocardium. Humanmyocardium is highly vascularized with numerous microvessels
of various sizes and capillaries. Resident heart microvascular pericytes can be identified by a combination of positive (pericyte) and negative
(vascular endothelial) cell surface markers. (a) Microvascular and capillary endothelial cells (ECs) were stained by CD31 (red) whilst CD146+
perivascular stromal cells (green) encircled CD31+ ECs (scale bar = 100𝜇m). (b) Enlargement of the dotted area in (a) further showed that
CD146+ human heart pericytes (hHPs, green) closely surround CD31+ ECs (red) (scale bar = 20 𝜇m). (c) CD146+ hHPs coexpressed pericyte
marker NG2 (scale bar = 50𝜇m). (d) hHPs expressing pericyte marker PDGFR𝛽 (red) encircled vWF+ ECs (green) (scale bar = 20𝜇m).
Nuclei are stained in blue by DAPI (4󸀠,6-diamidino-2-phenylindole).
improved cardiac contractility, superior to CD56+MCs [50].
The functional recovery was presumably attributable to the
significant increase of host angiogenesis and substantial
reduction of ventricular remodeling, myocardial fibrosis, and
chronic inflammation at the infarct site [50]. In particular,
PCs were shown to have highly active paracrine secretion of
trophic factors and cytokines including VEGF-A, PDGF-𝛽,
TGF-𝛽1, IL-6, LIF, COX-2, andHMOX-1, even under hypoxia
[50]. In addition to their paracrine function, direct cellular
involvement of PCs in cardiac repair was demonstrated by
PC homing to perivascular locations and PC-EC interaction
in vitro and in vivo as well as a fraction of PCs differentiating
into and/or fusing with cardiac cells [50]. These data suggest
that benefits of intramyocardial transplantation of PCs can
be attributed to multiple restorative mechanisms involving
paracrine effect, cellular interaction, and direct differentia-
tion.
Very recently, we have successfully identified human
heart pericytes (hHPs) based on their surface antigen expres-
sion (Figure 3) and purified hHPs by FACS from myocar-
dial biopsies [48]. hHPs (CD146+/CD34−/CD45−/CD56−/
CD117−) shared many similarities with their skeletal muscle-
derived counterparts and yet showed distinctive antigenic,
myogenic, and angiogenic characteristics [48]. Cultured
hHPs exhibited typical mesodermal multipotency, except
skeletal myogenesis, and displayed prevailing angiogenic
reactions under hypoxic conditions when compared with
isogenic muscle-derived PCs [48]. Our results suggest devel-
opmental and functional divergence of PCs due to anatom-
ical specification. Interestingly, two subpopulations of PCs
(Nestin−/NG2+, type-1, andNestin+/NG2+, type-2)with dif-
ferential developmental capacities have also been identified
within the skeletal muscle [67]. This further suggests that
the heterogeneity and developmental divergence of PCs exist
not only between PCs from different organs but also among
PCs within the same tissue. The tissue-specific signaling and
therapeutic potential of hHPs in cardiac regeneration are
currently under investigation. Collectively these data suggest
that PCs serve as potent regenerative units and growth fac-
tor/cytokine sources during tissue regeneration and represent
a promising stem cell reservoir, readily accessible throughout
the human body, for various therapeutic applications [68].
5.3.3. Adventitial Cells. Katare et al. investigated the efficacy
of ACs for treating ischemic heart disease in a mouse
MI model [52]. AC treatment improved overall cardiac
function and excelled BM-MSC treatment in terms of ame-
liorating left ventricular dilatation and wall thinning [52].
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AC treatment increased local neovascularization, improved
myocardial blood flow, and attenuated myocardial fibrosis,
cardiomyocyte apoptosis, and vascular permeability [52].
Mechanistically, the paracrine secretion of proangiogenic
factors and chemokines presumably activated the proangio-
genic and prosurvival Akt/eNOS/Bcl-2 signaling pathway.
The involvement of microRNA-132 (miR-132) as a novel
paracrine angiogenic stimulant and remodeling inhibitor was
demonstrated by blocking miR-132 function in ACs using
anti-miR-132, which in turn significantly decreased their
vascular supportive capacity in vitro, revascularization in
the ischemic myocardium, and cardiac reparative/protective
functions [52]. Very recently, a combinatory therapy with
c-kit+ cardiac stem cells and adventitial pericytes derived
from human saphenous vein has been shown to exhibit
additive benefits for cardiac regeneration [69]. Together
these data strongly support the therapeutic value of ACs in
cardiovascular diseases.
5.4. Skin Regeneration
5.4.1. Pericytes. The presence of mesenchymal cells, presum-
ably taking on the role of PCs in the healing wound, was first
observed in 1970 [70].The involvement ofmultipotent dermal
PCs in epidermal tissue renewal has been supported by the
significantly enhanced regenerative capacity of committed
human epidermal cells in organotypic coculture, presumably
through the augmented secretion of laminin-𝛼5 and indepen-
dent of angiogenesis, suggesting the importance of pericyte-
mediated remodeling of local ECM microenvironment [71].
The role of PCs in wound healing and cell-based wound
therapy was reviewed in [35].
5.5. Bone Regeneration
5.5.1. Myogenic Endothelial Cells. The potential of MECs
for bone regeneration has been examined in vitro and in
mice [28, 49]. MECs exhibited intense mineralization in
pellet culture only with the presence of bone morphogenetic
protein- (BMP-) 4, suggesting no spontaneous osteogenic
differentiation of MECs without an appropriate inductive
signal [49]. 𝜇CT imaging revealed that MECs transduced
with BMP-4 formed dense ectopic bone nodules when seeded
onto a gelatin sponge and implanted into intramuscular
pockets in immunodeficientmice [49]. Currently the potency
of MEC transplantation for the treatment of critical bone
defects is under investigation.
5.5.2. Pericytes. Together with ACs, human adipose-derived
PCs have been extensively studied for their bone regenerative
capacity [47, 72]. Interestingly, although most demographic
parameters, including age, gender, and menopause, did not
affect adipose PC yield, donors with body mass index (BMI)
less than 25 (nonoverweight) appeared to have higher PC
yield than obese donors (BMI > 30) [47]. Moreover, human
umbilical cord CD146+ perivascular cells have also been
demonstrated as a promising cell source for bone regenera-
tion [73].
5.5.3. Adventitial Cells. Combined with PCs, the skeletal
regenerative capacity of human adipose-derived ACs has
been explored [47, 72]. Human perivascular stem cells
(hPSCs), which comprised only PCs and ACs, were purified
from lipoaspirate SVF, seeded onto osteoinductive or control
collagen scaffolds, and implanted into either intramuscular
ectopic implantation model or critical-sized calvarial bone
injury model in immunodeficient mice [47, 72]. When com-
pared with unfractionated SVF, hPSCs formed significantly
more bone intramuscularly and led to dramatically greater
healing of critical-sized calvarial defects [47, 72]. Addi-
tionally, unlike BMP-2 which increased bone formation by
hPSCs in vivo but also induced an adipogenic response, Nel-
like molecule 1 (NELL-1) selectively enhanced osteogenesis
of hPSCs and therefore represents a novel osteoinductive
growth factor for hPSC-mediated skeletal regeneration [72].
Together recent studies suggest that ACs, like PCs, are func-
tionally superior MSC alternatives for regenerative purposes
and effortlessly accessible from dispensable tissues such as
lipoaspirate.
6. Conclusion
The capability to isolate subpopulations of hBVSCs marked a
major progress to understand the heterogeneous MSC entity
as well as their vascular/perivascular niches. Purified MECs,
PCs, andACs exhibited robust reparative/regenerative capac-
ities in many injured/defective tissues, often outperforming
unfractionatedMSCs.No tumorigenesis of any hBVSC subset
has been reported thus far, indicating their safety for transla-
tional applications.More preclinical studies with large animal
models are necessary to further validate the therapeutic safety
and efficacy of hBVSCs for clinical use. Currently researchers
have planned clinical trials using human pericytes in patients
with refractory myocardial ischemia [74]. In addition to
fresh tissue biopsies, we have been able to purify MECs and
PCs from long-term cryopreserved human primary skeletal
muscle cell cultures and further demonstrated their sustained
myogenic capacity in vivo [75]. This suggests the feasibility
to purify specific subset(s) of hBVSCs from either fresh
biopsy or banked human primary cells, ultimately facilitat-
ing customized regenerative medicine using personalized,
homogeneous therapeutic stem/progenitor cell population(s)
for a particular pathological condition.
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